Skye Bioscience Advances Obesity Treatment with New Formulation

Introduction

SKYE BIOSCIENCE INC (Nasdaq: SKYE) is a clinical-stage biotechnology company headquartered in San Diego. The firm is focused on developing peripherally-restricted CB1 receptor inhibitors intended to reduce excess body fat and improve metabolic health in patients with obesity and related conditions.

Corporate Structure

Punit S. Dhillon has served as President and Chief Executive Officer since 2020. Dhillon has over 20 years of experience in the life sciences sector, having raised more than $500 million in capital and established partnerships with companies including Merck, Genentech, and BMS. Under his leadership, Skye has formed a management team and board with expertise in early-stage biotech and clinical development. The company’s investor base includes specialist life-science funds and institutional holders, such as Schonfeld Strategic Advisors LLC, which reported a 5.22% stake as of March 31, 2025.

Recent Developments and News

On May 13, 2025, Skye Bioscience presented a clinical pharmacokinetic/pharmacodynamic (PK/PD) model at the European Congress on Obesity. The model demonstrated that peripheral—not central—CB1 inhibition can lead to weight loss while providing a wider therapeutic index. The model compared nimacimab with small-molecule CB1 inhibitors monlunabant and rimonabant, emphasizing its minimal penetration into the brain.

On May 19, 2025, Skye announced a collaboration with Arecor Therapeutics to develop a higher-concentration formulation of nimacimab using Arecor’s Arestat™ technology. This development aims to reduce injection volume, potentially improving patient compliance in the ongoing Phase 2a CBeyond™ trial.

Skye initiated its Phase 2 trial of nimacimab in August 2024 (ClinicalTrials.gov: NCT06577090), evaluating the antibody as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Topline data are anticipated in late Q3 or early Q4 2025.

The company filed a Current Report on Form 8-K on June 11, 2025, detailing material agreements and corporate developments under items 4.01, 5.07, and 9.01.

Financial and Strategic Analysis

As of June 23, 2025, SKYE shares closed at $2.96, up 37.04% on a volume of 6,824,517 shares. Key metrics from CNBC include:

• Market capitalization: $91.7 million
• Shares outstanding: 30.98 million
• EPS (TTM): –$0.83
• P/E (TTM): –3.57
• Beta: 1.67
• 52-week range: $1.14 (April 8, 2025) to $8.44 (June 27, 2024)

The negative EPS is indicative of ongoing investments in research and development. Skye’s strategic focus on a monoclonal antibody platform aims to address unmet needs in obesity by targeting metabolic pathways outside the central nervous system. The collaboration with Arecor may enhance nimacimab’s dosing profile, supporting its 18–21 day half-life and potential for once-weekly dosing. Institutional interest, as shown by Schonfeld’s 5.22% stake, reflects confidence in the asset’s distinct characteristics.

Market Position and Industry Context

Obesity prevalence in the U.S. is expected to affect nearly three-quarters of adults by 2025, with the weight-loss pharmaceutical market projected to exceed $100 billion in sales by 2030. Current GLP-1 receptor agonists provide significant weight loss but may lead to gastrointestinal side effects and variable patient responses. Small-molecule CB1 inhibitors have shown weight-loss effectiveness but can result in central side effects. Skye’s nimacimab, a peripherally-restricted CB1-inhibiting antibody, seeks to complement GLP-1 therapies by enhancing fat breakdown, reducing inflammation, and improving metabolic health without neuropsychiatric toxicity.

tl;dr

On May 13, 2025, Skye Bioscience presented clinical modeling that confirmed peripheral CB1 inhibition’s effectiveness for weight loss. Following that, on May 19, 2025, the company secured a formulation collaboration with Arecor to enhance nimacimab delivery. The Phase 2 CBeyond™ trial, initiated in August 2024, is on track for topline results in late Q3 or early Q4 2025. SKYE shares increased by 37.04% to $2.96 on June 23, 2025, indicating investor interest as critical data readouts approach.